TITLE

Effects of β-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis

AUTHOR(S)
Renner, S.; Rath, R.; Rust, P.; Lehr, S.; Frischer, Th.; Elmadfa, I.; Eichler, I.
PUB. DATE
January 2001
SOURCE
Thorax;Jan2001, Vol. 56 Issue 1, p48
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background -- Patients with cystic fibrosis (CF) have significantly decreased plasma concentrations of nutrient antioxidant vitamins, especially of β-carotene, which is thought to result from fat malabsorption and chronic pulmonary inflammation. The aim of this double blind, placebo controlled study was to investigate the effect of oral β-carotene supplementation for six months on clinical parameters. Methods -- Twenty four patients with CF were randomised to receive β-carotene 1 mg/kg/day (maximum 50 mg/day) for three months (high dose supplementation) and 10 mg/day for a further three months (low dose supplementation) or placebo. At monthly follow up visits the plasma β-carotene concentration, total antioxidant capacity, malondialdehyde (MDA) as a marker of lipid peroxidation, and clinical parameters (Shwachmann- Kulczycki score, body mass index (BMI), height, and lung function (FEV1) were assessed. The number of pulmonary exacerbations requiring antibiotic treatment (in days) three months before and during the study were evaluated. Results -- The plasma concentration of β-carotene increased significantly to the normal range during the three months of high dose supplementation (baseline 0.08 (0.04) μmol/l to 0.56 (0.38) μmol/l; p < 0.001) but decreased to 0.32 (0.19) μmol/l in the period of low dose supplementation. Initially raised plasma levels of MDA fell to normal levels and the total antioxidant capacity showed a non- significant trend towards improvement during high dose supplementation. Antibiotic treatment decreased significantly in the supplementation group from 14.5 (14.9) days/patient during the three months before the study to 9.8 (10.3) days/ patient during high dose supplementation (p=0.0368) and to 10.5 (9.9) days/patient during low dose supplementation, but increased in the placebo group. The Shwachmann-Kulczycki score, lung function, and BMI did not show any changes in either of the treatment groups. No adverse events were observed during the study period. Conclusion -- Oral β-carotene supplementation in a dose of 1 mg/kg/day only was effective in normalising the plasma concentration of β-carotene and resulted in a decrease in pulmonary exacerbations. These data suggest that patients with CF may benefit clinically from supplementation with β-carotene and further studies are warranted.
ACCESSION #
12948803

 

Related Articles

  • Aspergillus/Allergic Bronchopulmonary Aspergillosis in an Irish Cystic Fibrosis Population: A Diagnostically Challenging Entity. Chotirmall, Sanjay Haresh; Branagan, Peter; Gunaratnam, Cedric; McElvaney, Noel Gerard // Respiratory Care;Aug2008, Vol. 53 Issue 8, p1035 

    BACKGROUND: Patients with cystic fibrosis (CF) can become colonized by aspergillus, which can act as an allergen and cause allergic bronchopulmonary aspergillosis (ABPA). OBJECTIVE: To determine the rate of aspergillus colonization and ABPA in a population of Irish patients with CF. METHODS: In...

  • Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Gustafsson, P. M.; De Jong, P. A.; Tiddens, H. A. W. M.; Lindblad, A. // Thorax;Feb2008, Vol. 63 Issue 2, p129 

    Background: A sensitive and valid non-invasive marker of early cystic fibrosis (CF) lung disease is sought. The lung clearance index (LCI) from multiple-breath washout (MBW) is known to detect abnormal lung function more readily than spirometry in children and teenagers with CF, but...

  • Pharmaxis Releases Positive Results of Phase 3 Cystic Fibrosis Trial.  // RT: The Journal for Respiratory Care Practitioners;Jun2009, Vol. 22 Issue 6, p34 

    The article offers updates on the cystic fibrosis (CF) trial by Pharmaxis in New South Wales. The results of the international phase 3 of the trial for Bronchitol, a placebo for those with CF, was released by Pharmaxis. By the end of the 3rd phase, it was found that the placebo improved lung...

  • Modified Chrispin-Norman chest radiography score for cystic fibrosis: observer agreement and correlation with lung function. de Jong, P. A.; Achterberg, J. A.; Kessels, O. A. M.; van Ginneken, B.; Hogeweg, L.; Beek, F. J.; Terheggen-Lagro, S. W. J. // European Radiology;Apr2011, Vol. 21 Issue 4, p722 

    Objective: To test observer agreement and two strategies for possible improvement (consensus meeting and reference images) for the modified Chrispin-Norman score for children with cystic fibrosis (CF). Methods: Before and after a consensus meeting and after developing reference images three...

  • Impact of the CFTR-Potentiator Ivacaftor on Airway Microbiota in Cystic Fibrosis Patients Carrying A G551D Mutation. Bernarde, Cédric; Keravec, Marlène; Mounier, Jérôme; Gouriou, Stéphanie; Rault, Gilles; Férec, Claude; Barbier, Georges; Héry-Arnaud, Geneviève // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Background: Airway microbiota composition has been clearly correlated with many pulmonary diseases, and notably with cystic fibrosis (CF), an autosomal genetic disorder caused by mutation in the CF transmembrane conductance regulator (CFTR). Recently, a new molecule, ivacaftor, has been shown...

  • Percep��o da gravidade da doen�a em pacientes adultos com fibrose c�stica. Roth Dalcin, Paulo de Tarso; Rampon, Greice; Pasin, L�lian Rech; Becker, Sinara Corr�a; Ramon, Gretchem Mesquita; de Oliveira, Viviane Ziebell // Jornal Brasileiro de Pneumologia;jan2009, Vol. 35 Issue 1, p27 

    Objective: To evaluate the perception of disease severity in patients with cystic fibrosis (CF), investigating its relationship with clinical score, radiographic score, respiratory function tests, adherence to treatment and perception of self-care practices. Methods: Prospective, cross-sectional...

  • Unique Pattern of Pulmonary Function After Exercise in Patients With Cystic Fibrosis.  // Pediatric Exercise Science;Aug1994, Vol. 6 Issue 3, p275 

    The purpose of this study was to assess the incidence, degree, pattern, and time course of pulmonary function test (PFT) changes measured after a dynamic exercise challenge. Forced expiratory maneuvers were performed before and serially after a 7-min run-walk in 44 patients with cystic fibrosis...

  • Evidence for a Cystic Fibrosis Enteropathy. Adriaanse, Marlou P. M.; van der Sande, Linda J. T. M.; van den Neucker, Anita M.; Menheere, Paul P. C. A.; Dompeling, Edward; Buurman, Wim A.; Vreugdenhil, Anita C. E. // PLoS ONE;10/20/2015, Vol. 10 Issue 10, p1 

    Background: Previous studies have suggested the existence of enteropathy in cystic fibrosis (CF), which may contribute to intestinal function impairment, a poor nutritional status and decline in lung function. This study evaluated enterocyte damage and intestinal inflammation in CF and studied...

  • Wasting as an independent predictor of mortality in patients with cystic fibrosis. Sharma, R.; Florea, V. G.; Bolger, A. P.; Doehner, W.; Florea, N. D.; Coats, A. J. S.; Hodson, M. E.; Anker, S. D.; Henein, M. Y. // Thorax;Oct2001, Vol. 56 Issue 10, p746 

    Background-Cystic fibrosis (CF) is the most common life threatening autosomal recessive disorder in the white population. Wasting has long been recognised as a poor prognostic marker in CF. Whether it predicts survival independently of lung function and arterial blood gas tensions has not...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics